# 20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms (Study 165)

> **NCT01568229** · PHASE2 · TERMINATED · sponsor: **Amgen** · enrollment: 111 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** AMG 747
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01568229
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-05
- **Primary completion:** 2013-06
- **Final completion:** 2013-08
- **Target enrollment:** 111 (ACTUAL)
- **Why stopped:** Toxic Epidermal Necrolysis
- **Last updated:** 2014-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01568229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01568229, "20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms (Study 165)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01568229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*